Efficacy and safety of intragastric balloon for obesity in Korea
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Intragastric balloon (IGB) is the only available endoscopic bariatric and metabolic therapy in Korea. End-ball (Endalis) has the longest history of clinical use among the IGBs available in Korea. However, little clinical data on this system have been reported. In this study, we aimed to evaluate the efficacy and safety of End-ball in Korea. Methods: We performed a retrospective cohort study of patients who underwent IGB insertion (End-ball) from 2013 to 2019. Demographic and anthropometric data were collected. The efficacy and safety of IGB treatment were analyzed. Results: In total, 80 patients were included. Mean age was 33.7 years and 83.8% were female. Initial body mass index was 34.48±4.69 kg/m2. Body mass index reduction was 3.72±2.63 kg/m2 at the time of IGB removal. Percent of total body weight loss (%TBWL) was 10.76%±6.76%. Percentage excess body weight loss was 43.67%±27.59%. Most adverse events were minor, and 71.4% of participants showed nausea, vomiting, or abdominal pain. Conclusions: IGB treatment showed good efficacy and safety profile in Korean patients with obesity. In terms of %TBWL and percentage excess body weight loss, the efficacy was similar to that in the Western population.
Abstract
Background/Aims: Intragastric balloon (IGB) is the only available endoscopic bariatric and metabolic therapy in Korea. End-ball (Endalis) has the longest history of clinical use among the IGBs available in Korea. However, little clinical data on this system have been reported. In this study, we aimed to evaluate the efficacy and safety of End-ball in Korea. Methods: We performed a retrospective cohort study of patients who underwent IGB insertion (End-ball) from 2013 to 2019. Demographic and anthropometric data were collected. The efficacy and safety of IGB treatment were analyzed. Results: In total, 80 patients were included. Mean age was 33.7 years and 83.8% were female. Initial body mass index was 34.48±4.69 kg/m2. Body mass index reduction was 3.72±2.63 kg/m2 at the time of IGB removal. Percent of total body weight loss (%TBWL) was 10.76%±6.76%. Percentage excess body weight loss was 43.67%±27.59%. Most adverse events were minor, and 71.4% of participants showed nausea, vomiting, or abdominal pain. Conclusions: IGB treatment showed good efficacy and safety profile in Korean patients with obesity. In terms of %TBWL and percentage excess body weight loss, the efficacy was similar to that in the Western population.
참고문헌 (25)
- Swinburn BA, "The global obesity pandemic : shaped by global drivers and local environments", Lancet, 378, pp.804~814 (2011)
- Storm AC, "Endobariatrics : a primer", Clin Gastroenterol Hepatol, 16, pp.1701~1704 (2018)
- Sullivan S, "Endoscopic bariatric and metabolic therapies : new and emerging technologies", Gastroenterology, 152, pp.1791~1801 (2017)
- McCarty TR, "The current state of bariatric endoscopy", Dig Endosc, 33, pp.321~334 (2021)
- Štimac D, "Endoscopic treatment of obesity : from past to future", Dig Dis, 38, pp.150~162 (2020)
- Younghee Choe, "비만 치료를 위한 위풍선 삽입술의 단기 치료 성적", Korean Journal of Helicobacter Upper Gastrointestinal Research, 20(4), pp.318~323 (2020), 대한상부위장관ㆍ헬리코박터학회[DOI]
- Hyeon-Ju Pak, "Effects of intragastric balloon on obesity in obese Korean women for 6 months post removal", Nutrition Research and Practice, 15(4), pp.456~467 (2021), 한국영양학회[DOI]
- 김보연, "2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea", Journal of Obesity & Metabolic Syndrome, 30(2), pp.81~92 (2021), 대한비만학회[DOI]
- Tai CM, "Effectiveness of intragastric balloon treatment for obese patients : one-year follow-up after balloon removal", Obes Surg, 23, pp.2068~2074 (2013)
- Ohta M, "Initial Japanese experience with intragastric balloon placement", Obes Surg, 19, pp.791~795 (2009)
- Ganesh R, "The bioenteric intragastric balloon(BIB)as a treatment for obesity : poor results in Asian patients", Singapore Med J, 48, pp.227~231 (2007)
- Mui WL, "Intragastric balloon in ethnic obese Chinese : initial experience", Obes Surg, 16, pp.308~313 (2006)
- Joon Hyun Cho, "The Clinical and Metabolic Effects of Intragastric Balloon on Morbid Obesity and Its Related Comorbidities", Clinical Endoscopy, 54(1), pp.9~16 (2021), 대한소화기내시경학회[DOI]
- Laing P, "Filling the void : a review of intragastric balloons for obesity", Dig Dis Sci, 62, pp.1399~1408 (2017)
- Keren D, "Intragastric balloons for overweight populations : 1 year post removal", Obes Surg, 28, pp.2368~2373 (2018)
- Marrero Torres RJ, "Fluid-filled intragastric balloons are an effective and safe weight loss option across BMI and age ranges", Surg Endosc, 36, pp.5160~5166 (2022)
- ASGE Bariatric Endoscopy Task Force, "ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies", Gastrointest Endosc, 82, pp.425~438 (2015)
- Ribeiro IB, "Adverse events and complications with intragastric balloons : a narrative review(with video)", Obes Surg, 31, pp.2743~2752 (2021)
- Neto MG, "Brazilian Intragastric Balloon Consensus Statement(BIBC) : practical guidelines based on experience of over 40, 000 cases", Surg Obes Relat Dis, 14, pp.151~159 (2018)
- 탁영진, "Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review", The World Journal of Men's Health, 39(2), pp.208~221 (2021), 대한남성과학회[DOI]
- 김옥현, "Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity", Korean Journal of Family Medicine, 34(5), pp.298~306 (2013), 대한가정의학회
- Lewis KH, "Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort", Obesity(Silver Spring), 27, pp.591~602 (2019)
- Mehta A, "Impact of adjunctive pharmacotherapy with intragastric balloons for the treatment of obesity", Am Surg (2021)
- Sioulas AD, "Intragastric balloon left in the stomach for more than a year : two case reports", Obes Facts, 5, pp.436~439 (2012)
- Genco A, "Intragastric balloon for obesity treatment : results of a multicentric evaluation for balloons left in place for more than 6 months", Surg Endosc, 29, pp.2339~2343 (2015)